ADULT patients with severe Crohn's Disease who are stabilised for at least nine months on any brand of infliximab can now receive a Streamlined or Telephone Authority prescription for MSD's biosimilar Renflexis.
In 2015, the Federal Government estimated that the increased use of biosimilar medicines will deliver $880m in PBS savings by 2020.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Jun 18
